Danaher マネジメント
マネジメント 基準チェック /34
Danaherの CEO はRainer Blairで、 Sep2020年に任命され、 の在任期間は 5.75年です。 の年間総報酬は$ 23.80Mで、 5.9%給与と94.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.01%を直接所有しており、その価値は$ 13.23M 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と14.8年です。
主要情報
Rainer Blair
最高経営責任者
US$23.8m
報酬総額
| CEO給与比率 | 5.88% |
| CEO在任期間 | 5.8yrs |
| CEOの所有権 | 0.01% |
| 経営陣の平均在職期間 | 2.4yrs |
| 取締役会の平均在任期間 | 14.8yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 19
DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple
Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.ナラティブの更新 • May 02
DHR: Masimo Cash Acquisition Will Support Premium Future Earnings Multiple
Danaher’s updated analyst price target moves lower by about $8 per share to roughly $250, as analysts factor in more conservative assumptions for growth, profitability and future P/E multiples following a recent series of mostly downward target revisions across the Street. Analyst Commentary Recent research on Danaher reflects a mixed but generally cautious tone, with several price target cuts offset by one modest increase and a change in rating context at another company linked to Danaher’s pending acquisition activity.Seeking Alpha • Apr 22
Danaher Q1 2026 Earnings Update
Summary Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q’26. Life Sciences segment’s core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q’25. Management kept their core revenue guidance of ~3-6% but raised the high end of 2026 EPS guidance from $8.5 to $8.55. Read the full article on Seeking Alphaナラティブの更新 • Apr 16
DHR: Masimo Cash Deal Will Support Premium Future Earnings Multiple
Danaher’s analyst price target has been reset from about $264.91 to $257.73, as analysts factor in updated assumptions around profit margins, revenue growth, discount rates and future P/E, alongside mixed recent research that includes both target raises and cuts, as well as the planned Masimo acquisition. Analyst Commentary Recent research on Danaher reflects a split view, with some firms raising their price targets and others trimming them, while the planned Masimo acquisition sits at the center of many discussions about valuation and execution risk.ナラティブの更新 • Apr 01
DHR: Cash Deal For Masimo Will Support Premium Future Earnings Multiple
Analysts have nudged Danaher’s price targets higher by low double digit dollar amounts, pointing to updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the key drivers behind the revised dollar values. Analyst Commentary Recent research has focused on how Danaher’s valuation reflects expectations for future execution, especially in light of the planned Masimo acquisition and refreshed targets across the life science tools peer group.ナラティブの更新 • Mar 18
DHR: Cash Acquisition Will Support Re Rating And Premium Earnings Multiple
Analysts have nudged their price targets on Danaher higher by a few dollars into the mid $260s, citing a series of upward target revisions across the Street and support from the announced Masimo acquisition at $180 per share in cash. Analyst Commentary Recent research around Danaher has centered on the Masimo acquisition agreement at $180 per share in cash and a cluster of higher price targets that place the stock in the mid $260s to around $270.ナラティブの更新 • Mar 04
DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple
The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.ナラティブの更新 • Feb 17
DHR: Masimo Deal And Higher Future P/E Will Support Premium Multiple
Danaher’s updated analyst price target edges slightly lower to about $265, as analysts balance modest tweaks to revenue growth, profit margin and P/E assumptions with a broadly supportive run of recent target increases across the Street. Analyst Commentary Recent Street research on Danaher is clustered around higher price targets, with several bullish analysts lifting their numbers by single digit to low double digit dollar amounts.ナラティブの更新 • Feb 03
DHR: Higher Future P/E Assumptions Will Support Premium Multiple Through Soft 2026 Outlook
Analysts have nudged their average price target for Danaher higher, with our fair value estimate moving from US$261.50 to about US$265.23. This change is supported by a modestly higher assumed future P/E multiple and by Street research that has generally lifted targets in the life science tools sector.ナラティブの更新 • Jan 19
DHR: Share Repurchases And Soft 2026 Outlook Will Support Premium Multiple
Analysts have nudged their price targets on Danaher higher, reflected in a fair value update from US$259.23 to US$261.50, citing refreshed views on revenue growth, profit margins, and future P/E expectations in recent research. Analyst Commentary Recent price target moves on Danaher point to refreshed views on how the company could execute on growth plans, manage profitability, and justify its current P/E profile.ナラティブの更新 • Jan 05
DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple
Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.ナラティブの更新 • Dec 19
DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers
Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.ナラティブの更新 • Dec 04
DHR: Share Repurchases Will Support Premium Multiple Despite Slower Recovery Uncertainty
Danaher's fair value estimate has been nudged slightly higher to approximately $255.67 from about $254.20, as analysts balance still premium valuations and tempered growth expectations with signs of stabilization in key Life Sciences and Diagnostics markets. Analyst Commentary Recent Street research reflects a more balanced, wait and see stance on Danaher as investors weigh premium valuation levels against a slower growth trajectory and a gradual recovery in key end markets.ナラティブの更新 • Nov 20
DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside
Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.ナラティブの更新 • Nov 04
DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds
Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.ナラティブの更新 • Oct 21
Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher
Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.ナラティブの更新 • Sep 11
Advanced Diagnostics And Personalized Therapies Will Expand Global Markets
Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.分析記事 • Aug 01
Some May Be Optimistic About Danaher's (NYSE:DHR) Earnings
Danaher Corporation's ( NYSE:DHR ) recent soft profit numbers didn't appear to worry shareholders, as the stock price...分析記事 • Jul 12
Is Danaher Corporation (NYSE:DHR) Trading At A 33% Discount?
Key Insights Danaher's estimated fair value is US$304 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Mar 31
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Summary Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years. I maintain a buy rating on DHR stock due to its strong long-term growth prospects and attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Mar 22
Danaher: Near 5-Year Low Is A Great Entry Point
Summary Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Danaher: Self-Inflicted Pessimism?
Summary Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company’s strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher’s bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment. Valuation analysis indicates the stock is currently undervalued, with potential for significant upside as market conditions improve and growth returns, making it a buy. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued
Summary Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles, Danaher has strong growth potential driven by secular tailwinds like an aging population and technological advancements in diagnostics. The company exhibits a wide economic moat due to high switching costs and stable margins, but its RoIC is below the ideal threshold. Currently, Danaher is overvalued with high P/E and P/FCF ratios, making it a "Hold" rather than a buy, pending future performance improvements. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Summary Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors. Trading at a reasonable valuation, Danaher is poised for a rebound with expected double-digit EPS growth, making it an excellent choice for long-term accumulation. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Danaher: A Resilient And Solid Company With Growth Potential
Summary Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduced their excess of COVID-19-related products. So, Danaher expects a further boost in its sales. The company has been successful in generating growth through acquiring other companies. In the last ten years, half of Danaher's growth has come due to this strategy. Read the full article on Seeking AlphaSeeking Alpha • Oct 25
Understanding Danaher's Cautiousness
Summary Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 27 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$24m | US$1m | US$4b |
| Sep 26 2025 | n/a | n/a | US$4b |
| Jun 27 2025 | n/a | n/a | US$3b |
| Mar 28 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$22m | US$1m | US$4b |
| Sep 27 2024 | n/a | n/a | US$4b |
| Jun 28 2024 | n/a | n/a | US$4b |
| Mar 29 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$1m | US$4b |
| Sep 29 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$20m | US$1m | US$6b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jul 01 2022 | n/a | n/a | US$6b |
| Apr 01 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$17m | US$1m | US$5b |
| Oct 01 2021 | n/a | n/a | US$6b |
| Jul 02 2021 | n/a | n/a | US$5b |
| Apr 02 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$10m | US$949k | US$4b |
| Oct 02 2020 | n/a | n/a | US$3b |
| Jul 03 2020 | n/a | n/a | US$3b |
| Apr 03 2020 | n/a | n/a | US$3b |
| Dec 31 2019 | US$7m | US$840k | US$2b |
報酬と市場: Rainerの 総報酬 ($USD 23.80M ) は、 US市場 ($USD 14.81M ) の同規模の企業の平均を上回っています。
報酬と収益: Rainerの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Rainer Blair (62 yo)
5.8yrs
在職期間
US$23,795,280
報酬
Mr. Rainer M. Blair serves as an Independent Non-Executive Director at Nestlé S.A. since April 20, 2023. He serves as President, Chief Executive Officer and Director at Danaher Corporation since September...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder & Chairman | 43.4yrs | データなし | 5.97% $ 8.0b | |
| President | 5.8yrs | US$23.80m | 0.0099% $ 13.2m | |
| Co-Founder & Director | 43.4yrs | データなし | 4.77% $ 6.4b | |
| Senior VP & Chief Science Officer | 5.5yrs | US$6.24m | 0.0011% $ 1.5m | |
| Executive Vice President | less than a year | US$7.97m | 0.0040% $ 5.4m | |
| Executive VP of Biotechnology Group & CEO of Cytiva | 2.4yrs | US$11.26m | 0.00059% $ 786.8k | |
| Executive Vice President of Diagnostics Platform | 1.9yrs | US$11.30m | 0.00080% $ 1.1m | |
| Executive VP & CFO | less than a year | データなし | 0.0011% $ 1.4m | |
| VP & Chief Accounting Officer | 4.4yrs | データなし | 0.00098% $ 1.3m | |
| Chief Technology & AI Officer | less than a year | データなし | データなし | |
| Vice President of Investor Relations | no data | データなし | データなし | |
| Senior VP & Chief Legal Officer | less than a year | データなし | データなし |
2.4yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: DHRの経営陣は 経験豊富 であると考えられます ( 2.4年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder & Chairman | 43.4yrs | データなし | 5.97% $ 8.0b | |
| President | 5.8yrs | US$23.80m | 0.0099% $ 13.2m | |
| Co-Founder & Director | 43.4yrs | データなし | 4.77% $ 6.4b | |
| Independent Director | 27.4yrs | US$351.03k | 0.012% $ 16.4m | |
| Independent Director | 17.4yrs | US$373.53k | 0.0023% $ 3.1m | |
| Independent Director | 9.3yrs | US$351.03k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | 5.2yrs | データなし | データなし | |
| Lead Independent Director | 20.5yrs | US$413.53k | 0.0031% $ 4.1m | |
| Member of Scientific Advisory Board | 5.2yrs | データなし | データなし | |
| Independent Director | 14.8yrs | US$379.53k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$378.53k | 0% $ 0 |
14.8yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: DHRの 取締役会 は経験豊富で 経験豊富 です ( 14.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/10 22:01 |
| 終値 | 2026/06/10 00:00 |
| 収益 | 2026/03/27 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Danaher Corporation 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。45
| アナリスト | 機関 |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |